Besides suppressing Raf‐mediated tumor proliferation, sorafenib exhibits anti–vascularization effects by inhibiting angiogenic stimulators including platelet‐derived growth factor receptors (PDGFR‐β) and vascular endothelial growth factor receptors (VEGFR).[37] Lenvatinib, another first‐line TKI, has been shown to target aberrantly activated FGFR in HCC.[38] These studies suggest targeting pathways involving VEGFR and FGFR could be beneficial for the treatment of HCC patients. Here, PDGFRB is linked to neoplasm.